Dr. Brian Jonas, MD
Claim this profileUniversity of California Davis Comprehensive Cancer Center
Expert in T-Lymphoblastic Leukemia/Lymphoma
Expert in Acute Myeloid Leukemia
20 reported clinical trials
44 drugs studied
About Brian Jonas, MD
Education:
- Obtained an MD from UC Davis School of Medicine.
- Earned a PhD in Biochemistry and Molecular Biology from UC Davis School of Medicine.
- Holds a B.A. in Molecular & Cell Biology and History from UC Berkeley.
Experience:
- Completed internship, residency, and fellowship in Hematology and Oncology at Stanford University School of Medicine.
- Serves as an Associate Professor of Medicine in the Division of Hematology and Oncology at the University of California, Davis.
- Leads the Acute Leukemia and MDS research program at UC Davis Comprehensive Cancer Center.
- Chairs the Hematologic Malignancies Disease Team at UC Davis Comprehensive Cancer Center.
- Focuses on developmental therapeutics and biomarker development in hematologic malignancies.
Area of expertise
1T-Lymphoblastic Leukemia/Lymphoma
Global LeaderFLT3 positive
PML-RARA negative
D835 positive
2Acute Myeloid Leukemia
Global LeaderFLT3 positive
D835 positive
PML-RARA negative
Affiliated Hospitals
Clinical Trials Brian Jonas, MD is currently running
Vyxeos
for Acute Myeloid Leukemia
This phase II trial studies the side effects and how well Vyxeos works in treating patients with intermediate and high-risk acute myeloid leukemia who have failed an initial cycle of standard cytarabine and daunorubicin chemotherapy. Vyxeos is a combination of both chemotherapy drugs cytarabine and daunorubicin contained in a liposome. Drugs used in chemotherapy, such as cytarabine and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cytarabine and daunorubicin given together in liposomes may have fewer side effects and work better than cytarabine and daunorubicin given alone in patients with acute myeloid leukemia.
Recruiting3 awards Phase 1 & 213 criteria
Ibrutinib + Blinatumomab
for Acute Lymphoblastic Leukemia
This phase II trial studies how well ibrutinib and blinatumomab work in treating patients with B acute lymphoblastic leukemia that has come back or is not responding to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as blinatumomab, may interfere with the ability of cancer cells to grow and spread. Giving ibrutinib and blinatumomab may work better in treating patients with relapsed or refractory B acute lymphoblastic leukemia.
Recruiting1 award Phase 212 criteria
More about Brian Jonas, MD
Clinical Trial Related4 years of experience running clinical trials · Led 20 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Brian Jonas, MD has experience with
- Venetoclax
- Azacitidine
- Cytarabine
- Liposome-encapsulated Daunorubicin-Cytarabine
- Daunorubicin Hydrochloride
- Decitabine
Breakdown of trials Brian Jonas, MD has run
T-Lymphoblastic Leukemia/Lymphoma
Acute Myeloid Leukemia
Myeloid Leukemia
Acute Myelogenous Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Brian Jonas, MD specialize in?
Brian Jonas, MD focuses on T-Lymphoblastic Leukemia/Lymphoma and Acute Myeloid Leukemia. In particular, much of their work with T-Lymphoblastic Leukemia/Lymphoma has involved FLT3 positive patients, or patients who are PML-RARA negative.
Is Brian Jonas, MD currently recruiting for clinical trials?
Yes, Brian Jonas, MD is currently recruiting for 9 clinical trials in Sacramento California. If you're interested in participating, you should apply.
Are there any treatments that Brian Jonas, MD has studied deeply?
Yes, Brian Jonas, MD has studied treatments such as Venetoclax, Azacitidine, Cytarabine.
What is the best way to schedule an appointment with Brian Jonas, MD?
Apply for one of the trials that Brian Jonas, MD is conducting.
What is the office address of Brian Jonas, MD?
The office of Brian Jonas, MD is located at: University of California Davis Comprehensive Cancer Center, Sacramento, California 95817 United States. This is the address for their practice at the University of California Davis Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.